INSP:NYE-Inspire Medical Systems, Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 187.00

Change

+0.18 (+0.10)%

Market Cap

USD 4.98B

Volume

0.27M

Avg Analyst Target

USD 246.67 (-6.92%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

+1.20 (+0.99%)

USD214.85B 34.06 23.08
MDT Medtronic plc

+0.20 (+0.15%)

USD176.47B 49.36 25.53
SYK Stryker Corporation

-2.06 (-0.76%)

USD102.17B 49.65 29.13
EW Edwards Lifesciences Corporati..

+1.42 (+1.25%)

USD70.42B 49.17 59.18
BSX Boston Scientific Corporation

-0.34 (-0.74%)

USD65.19B 124.34 43.27
ZBH Zimmer Biomet Holdings, Inc

-9.30 (-5.71%)

USD34.07B 59.95 24.06
BIO-B Bio-Rad Laboratories, Inc

N/A

USD21.80B 5.21 3.85
BIO Bio-Rad Laboratories, Inc

+9.22 (+1.25%)

USD21.71B 5.49 3.91
SNN Smith & Nephew plc

-0.14 (-0.35%)

USD17.99B 32.48 22.74
PEN Penumbra, Inc

-3.12 (-1.18%)

USD9.71B 937.69 490.23

ETFs Containing INSP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.58% 30% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.58% 30% F 20% F
Trailing 12 Months  
Capital Gain 83.35% 96% A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.35% 96% A 85% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 64.17% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.17% 96% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 70.09% 17% F 10% F
Risk Adjusted Return 91.56% 70% C- 89% B+
Market Capitalization 4.98B 52% F 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 22.34 4% F 4% F
Price / Cash Flow Ratio -93.97 84% B 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.62% 29% F 15% F
Return on Invested Capital -26.89% 20% F 5% F
Return on Assets -15.79% 24% F 3% F
Debt to Equity Ratio 10.77% 75% C 86% B
Technical Ratios  
Short Ratio 3.65 44% F 26% F
Short Percent 3.26% 50% F 49% F
Beta 1.64 4% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector